

BME – GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 4th November 2022

COMMUNICATION – OTHER RELEVANT INFORMATION

FACEPHI BIOMETRIA S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter “Facephi” or “the Company”, interchangeably).

Facephi announces the signature of its technology licensing agreement with a Fintech in the Dominican Republic, thus initiating its collaboration with one of the most important banks in the country.

This new agreement is of huge strategic importance for the implementation of the company's technology; since it means the opening of a new market in the Dominican Republic, strengthening Facephi's presence in LATAM.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors